Hypoparathyroidism is a rare endocrine disorder characterized by insufficient PTH secretion leading to hypocalcemia, hyperphosphatemia, and neuromuscular excitability including tetany. The most common cause (~75–78% of cases) is iatrogenic injury during anterior neck surgery; the remainder are autoimmune, genetic, or infiltrative. [1-2] Estimated prevalence is 23–37 per 100,000 person-years. [1][3]
1. History
- Key HPI: Onset and duration of paresthesias (perioral, fingertips), muscle cramps, stiffness, spasms, or carpopedal spasm [4]
- Timing/triggers: Recent neck surgery (thyroidectomy, parathyroidectomy), physiologic stress, febrile illness, pregnancy/lactation [4-5]
- Severity/progression: Mild tingling → sustained cramps → frank tetany → laryngospasm → seizures [1][4]
- Associated symptoms: Confusion, irritability, depression, lightheadedness, dyspnea, palpitations, visual changes [4][6]
- Important negatives: No diarrhea/malabsorption (vitamin D deficiency), no alcohol use (hypomagnesemia), no renal disease history, no diuretic use
2. Alarm Features
- Laryngospasm — airway emergency [1]
- Seizures — may be the presenting symptom, especially in children [1][5]
- QTc prolongation → torsades de pointes → ventricular fibrillation [4]
- Serum calcium <7.0 mg/dL with progressive symptoms despite oral therapy [4]
- Altered mental status, hemodynamic instability
- Stridor or respiratory distress
3. Medications
- Acute treatment: IV calcium gluconate (preferred for peripheral access); calcium chloride via central line only [1][4]
- Maintenance: Oral calcium carbonate (40% elemental Ca) or calcium citrate (21% elemental Ca) + calcitriol 0.25–0.5 µg BID [4][7]
- Adjuncts: Magnesium oxide 400 mg daily–BID if hypomagnesemia present; thiazide diuretics (HCTZ 12.5–50 mg) for refractory hypercalciuria [4]
- PTH replacement: Palopegteriparatide (Yorvipath) — FDA-approved for chronic hypoparathyroidism when conventional therapy is inadequate [8-10]
- Medication contributors to hypocalcemia: Loop diuretics, bisphosphonates, denosumab, cisplatin, aminoglycosides, PPIs (impair calcium absorption), phenytoin, foscarnet
- Caution: Separate calcium from levothyroxine by ≥1 hour before or 3 hours after; calcium carbonate requires acidic gastric pH — use calcium citrate in patients on PPIs [4]
4. Diet
- Calcium-rich diet emphasized from diagnosis onward (dairy, fortified foods, leafy greens) [5]
- Adequate vitamin D intake per age-based recommendations
- Avoid excessive phosphate-rich foods (processed foods, colas) which worsen hyperphosphatemia
- Ensure adequate hydration to reduce nephrolithiasis risk
- Long-term: target dietary calcium to reduce supplement pill burden
5. Review of Systems
- Neuro: Paresthesias, numbness, seizures, cognitive changes, headache, impaired vision [4][6]
- Cardiac: Palpitations, syncope, dyspnea [6]
- Pulmonary: Wheezing, bronchospasm, stridor (laryngospasm) [6]
- Psych: Anxiety, depression, emotional instability, "brain fog" [4]
- MSK: Muscle cramps, spasms, stiffness [1]
- GI: Abdominal pain [6]
- Renal: History of kidney stones, flank pain (nephrolithiasis/nephrocalcinosis) [1]
- Ophthalmologic: Visual changes (posterior subcapsular cataracts in chronic disease) [1][3]
6. Collateral History and Family History
- Surgical history: Prior thyroidectomy, parathyroidectomy, radical neck dissection — timing and extent [1][11]
- Family history: Autoimmune diseases (type 1 DM, Addison's, thyroiditis) — suggests autoimmune polyglandular syndrome/APECED [1]
- Genetic syndromes: 22q11.2 deletion (DiGeorge), autosomal dominant hypocalcemia (CaSR mutations), HDR syndrome (GATA3), mitochondrial disorders [1][5]
- Social context: Chronic candidiasis (APECED), developmental delay (22q11.2DS), iron overload (thalassemia/hemochromatosis) [12]
7. Risk Factors
- Anterior neck surgery — by far the most common cause (total thyroidectomy: 20–30% transient, 1–7% permanent) [11]
- Autoimmune disease — most common nonsurgical cause [11][13]
- Genetic conditions: 22q11.2 deletion, activating CaSR mutations, AIRE gene mutations [1]
- Severe magnesium depletion: Alcoholism, malnutrition, diuretics, cisplatin, aminoglycosides [1][13]
- Iron/copper overload: Thalassemia, hemochromatosis, Wilson's disease [12]
- Radiation: Neck radiation (rare) [3]
- Infiltrative disease: Metastatic disease to parathyroids (rare) [12]
8. Differential Diagnosis
The following algorithm from the American Academy of Family Physicians provides a systematic approach to evaluating hypocalcemia:
- Vitamin D deficiency — most common cause of hypocalcemia overall; PTH will be elevated (secondary hyperparathyroidism) [6][14]
- Hypomagnesemia — impairs PTH secretion and action; must correct Mg before Ca will respond [4][13]
- Pseudohypoparathyroidism — PTH resistance; PTH elevated, hypocalcemia + hyperphosphatemia; Albright hereditary osteodystrophy features [12]
- CKD with secondary hyperparathyroidism — elevated PTH, elevated creatinine [6]
- Hungry bone syndrome — post-parathyroidectomy or post-thyroidectomy for Graves' disease [4]
- Acute pancreatitis — saponification of calcium
- Hyperventilation/respiratory alkalosis — decreased ionized calcium, total calcium normal
- Sepsis/critical illness — multifactorial hypocalcemia
- Rhabdomyolysis — calcium deposition in damaged muscle
9. Past Medical History
- Prior neck surgery (type, extent, complications)
- Previous episodes of hypocalcemia or tetany
- Known autoimmune conditions (thyroiditis, adrenal insufficiency, type 1 DM)
- Renal disease (affects vitamin D activation, calcium handling)
- History of nephrolithiasis or nephrocalcinosis [1][3]
- Cataracts (posterior subcapsular — chronic hypoparathyroidism) [1]
- Basal ganglia calcifications [1]
- Seizure history
10. Physical Exam
- Vital signs: Hypotension possible; assess for stridor
- Chvostek sign: Tapping over facial nerve (preauricular) → ipsilateral facial muscle twitching (present at baseline in up to 25% of normals — low specificity) [4]
- Trousseau sign: Inflate BP cuff above systolic for 3 minutes → carpopedal spasm (more specific) [4]
- Neuromuscular: Hyperreflexia, muscle fasciculations, carpopedal spasm, tetany
- Airway: Stridor, voice changes (laryngospasm)
- Surgical scar: Anterior neck scar suggesting prior thyroid/parathyroid surgery
- Dysmorphic features: Consider 22q11.2DS (micrognathia, palatal abnormalities) or Albright hereditary osteodystrophy (short stature, brachydactyly, round facies) [5][12]
- Skin/nails: Dry skin, brittle nails, candidiasis (APECED)
11. Lab Studies
12. Imaging
- Renal ultrasound: Assess for nephrocalcinosis and nephrolithiasis — recommended intermittently in chronic disease [1][5]
- CT head (non-contrast): Basal ganglia calcifications — common in chronic hypoparathyroidism [1]
- Slit-lamp exam: Posterior subcapsular cataracts [1][3]
- DEXA scan: Bone mineral density often increased (low bone turnover); assess in postmenopausal women and men >50 [10]
- Imaging is not required acutely for the diagnosis of tetany — this is a clinical and biochemical diagnosis
13. Special Tests
- Corrected calcium formula: Corrected Ca = measured Ca + 0.8 × (4.0 − albumin)
- Chvostek and Trousseau signs: Bedside provocative tests [4]
- Genetic testing: Targeted gene panels for nonsurgical cases (CaSR, GCM2, GATA3, AIRE, 22q11.2 FISH/microarray) [1]
- Antibody testing: Anti-CaSR antibodies, anti-NALP5 antibodies in suspected autoimmune cases
- Point-of-care iCa: Rapid confirmation in the ED
14. ECG
- QTc prolongation — the hallmark ECG finding of hypocalcemia [4]
- Prolonged ST segment (distinct from QT prolongation due to hypokalemia, which prolongs the T wave)
- Torsades de pointes — life-threatening arrhythmia in severe hypocalcemia [4]
- Bradycardia or heart block possible
- Indications for ECG: All patients with symptomatic hypocalcemia, serum Ca <7.0 mg/dL, or before initiating IV calcium [4]
- Continuous cardiac monitoring required during IV calcium infusion [1]
15. Assessment
Hypoparathyroidism presenting with tetany represents acute symptomatic hypocalcemia requiring urgent intervention. Severity stratification:
- Mild: Paresthesias, mild cramps, Ca 7.5–8.5 mg/dL → oral calcium ± calcitriol [4]
- Moderate: Sustained cramps, Chvostek/Trousseau positive, Ca declining despite oral therapy → add calcitriol, consider IV calcium [4]
- Severe: Tetany, laryngospasm, seizures, QTc prolongation, Ca <7.0 mg/dL → IV calcium gluconate + cardiac monitoring [1][4]
Complications to consider: airway compromise (laryngospasm), cardiac arrhythmias, seizures, and in chronic disease — nephrocalcinosis, renal insufficiency, basal ganglia calcifications, cataracts. [1][3]
16. Treatment Plan
Acute Stabilization (ED/Inpatient)
- IV calcium gluconate: 1–2 g (10–20 mL of 10% solution = 93–186 mg elemental Ca) in 50 mL D5W over 10–20 minutes [1][4]
- Follow with continuous calcium gluconate drip to prevent recurrence while initiating oral therapy [1]
- Cardiac monitoring throughout IV calcium administration [1][4]
- Check and correct magnesium (Mg <1.6 mg/dL → MgO 400 mg PO daily–BID or IV MgSO₄) [4]
Oral Therapy Initiation
- Calcium carbonate 1–3 g/day (400–1200 mg elemental Ca) in divided doses with meals; or calcium citrate if on PPI [4]
- Calcitriol 0.25–0.5 µg BID [4][7]
- Optimize 25-OH vitamin D levels (cholecalciferol supplementation) [1][5]
Refractory/Chronic Disease
- Thiazide diuretics (HCTZ 12.5–50 mg daily) to reduce urinary calcium losses [4]
- Palopegteriparatide (Yorvipath) — FDA-approved for adults with chronic hypoparathyroidism inadequately controlled on conventional therapy; once-daily subcutaneous injection [8-10]
The following algorithm illustrates a stratified approach to calcium and vitamin D supplementation in the postoperative setting:
17. Disposition
- Admit (ICU or telemetry): Serum Ca <7.0 mg/dL, tetany, seizures, laryngospasm, QTc prolongation, requiring IV calcium drip [4]
- Admit (floor/observation): Symptomatic hypocalcemia requiring IV bolus, inability to tolerate oral intake, unstable calcium levels
- Discharge: Mild symptoms, Ca ≥7.5 mg/dL and rising on oral therapy, tolerating PO, reliable follow-up within 24–48 hours [4]
- Consult endocrinology: All new diagnoses of hypoparathyroidism, refractory hypocalcemia, suspected genetic/autoimmune etiology [1][10]
18. Follow Up / Return Precautions
- Follow-up timing: Recheck serum calcium within 24–48 hours of discharge, then every 1–2 weeks during dose titration, then every 3–6 months once stable [5][18]
- Monitor: Serum calcium, phosphorus, magnesium, creatinine, 24-hour urine calcium, urine Ca/Cr ratio [1][5]
- Renal ultrasound: Periodically to screen for nephrocalcinosis/nephrolithiasis [5]
Return immediately for
- Numbness/tingling worsening or spreading
- Muscle spasms that do not resolve
- Difficulty breathing, voice changes, or throat tightness (laryngospasm)
- Seizure activity
- Palpitations, lightheadedness, or syncope
- Confusion or altered mental status
Patient counseling: Take calcium supplements with meals in divided doses (not all at once); separate from levothyroxine; maintain calcium-rich diet; avoid phosphate-heavy processed foods; do not abruptly stop calcitriol. [1][4]
References
1. Hypoparathyroidism. — Gafni RI, Collins MT. The New England Journal of Medicine. 2019.
2. Hypoparathyroidism: Diagnosis, Management and Emerging Therapies. — Khan S, Khan AA. Nature Reviews. Endocrinology. 2025.
3. Epidemiology and Diagnosis of Hypoparathyroidism. — Clarke BL, Brown EM, Collins MT, et al. The Journal of Clinical Endocrinology and Metabolism. 2016.
4. American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults. — Orloff LA, Wiseman SM, Bernet VJ, et al. Thyroid : Official Journal of the American Thyroid Association. 2018.
5. Health Supervision for Children With 22q11.2 Deletion Syndrome: Clinical Report. — Scheuerle AE, Geleske TA, Merchant N, Goldenberg PC. Pediatrics. 2025.
6. Parathyroid Disorders. — Sell J, Ramirez S, Partin M. American Family Physician. 2022.
7. FDA Drug Label. — Updated date: 2018-08-22. Food and Drug Administration.
8. FDA Orange Book. — FDA Orange Book. 2026.
9. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. — Khan AA, Rubin MR, Schwarz P, et al. Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research. 2023.
10. Best Practice Recommendations for the Diagnosis and Management of Hypoparathyroidism. — Khan AA, Ali DS, Bilezikian JP, et al. Metabolism: Clinical and Experimental. 2025.
11. Presentation of Hypoparathyroidism: Etiologies and Clinical Features. — Shoback DM, Bilezikian JP, Costa AG, et al. The Journal of Clinical Endocrinology and Metabolism. 2016.
12. Hypoparathyroidism. — Shoback D. The New England Journal of Medicine. 2008.
13. Medical Hypoparathyroidism. — Siraj N, Hakami Y, Khan A. Endocrinology and Metabolism Clinics of North America. 2018.
14. Diagnosis and Management of Hypocalcemia. — Pepe J, Colangelo L, Biamonte F, et al. Endocrine. 2020.
15. Hypoparathyroidism: Genetics and Diagnosis. — Mannstadt M, Cianferotti L, Gafni RI, et al. Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research. 2022.
16. Hypoparathyroidism. — Bilezikian JP. The Journal of Clinical Endocrinology and Metabolism. 2020.
17. Guideline From the Brazilian Society of Surgical Oncology and Brazilian College of Surgeons in Preventing and Managing Acute Hypoparathyroidism After Thyroid Surgery. — Santa Ritta Barreira CE, Kowalski LP, Dias FL, et al. Journal of Surgical Oncology. 2024.
18. Consensus-Based Recommendations for the Diagnosis, Treatment, and Monitoring of Hypoparathyroidism: Insights From the DACH Region. — Tsourdi E, Amrein K, Meier C, et al. Calcified Tissue International. 2025.